- Home
- DOMH vs KZIA Comparison
DOMH vs KZIA Comparison
Compare DOMH & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOMH | KZIA |
|---|---|---|
| Founded | 1967 | 1994 |
| Country | United States | Australia |
| Employees | N/A | 6 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.1M | 186.7M |
| IPO Year | 2010 | 2002 |
Fundamental Metrics
Financial Performance| Metric | DOMH | KZIA |
|---|---|---|
| Price | $2.20 | $11.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 154.3K | ★ 263.3K |
| Earning Date | 05-12-2026 | 06-04-2026 |
| Dividend Yield | ★ 23.45% | N/A |
| EPS Growth | ★ 34.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $123,104,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 578.41 | N/A |
| 52 Week Low | $1.91 | $4.86 |
| 52 Week High | $8.40 | $17.40 |
Technical Indicators
Market Signals| Indicator | DOMH | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 31.05 | 38.77 |
| Support Level | N/A | $7.25 |
| Resistance Level | $3.29 | $14.85 |
| Average True Range (ATR) | 0.12 | 1.15 |
| MACD | -0.05 | -0.30 |
| Stochastic Oscillator | 12.82 | 5.04 |
Price Performance
Historical ComparisonAbout DOMH Dominari Holdings Inc.
Dominari Holdings Inc is a holding company that, through its various subsidiaries, is engaged in wealth management, investment banking, sales and trading, asset management, and insurance. In addition to capital investment, Dominari provides management support to the executive teams of its subsidiaries, helping them to operate efficiently and reduce costs under a streamlined infrastructure. The Company operates in two reportable business segments: Dominari Financial and Legacy AIkido, with the majority of revenue from Dominari Financial.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.